Seven Eight Capital’s Core Laboratories CLB Stock Holding History

Seven Eight Capital’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-12,226	Closed	-$248K	–	550
2020 Q2	$248K	Buy	+12,226	New	+$219K	0.18%	226
2019 Q3	–	Sell	-33,401	Closed	-$1.75M	–	609
2019 Q2	$1.75M	Buy	33,401 +10,200	+44%	+$598K	0.09%	283
2019 Q1	$1.6M	Buy	+23,201	New	+$1.56M	0.08%	282
2017 Q3	–	Sell	-701	Closed	-$71K	–	474
2017 Q2	$71K	Buy	+701	New	+$75.6K	0.01%	464
2015 Q1	–	Sell	-3,393	Closed	-$408K	–	518
2014 Q4	$408K	Buy	+3,393	New	+$446K	0.68%	33
2014 Q3	–	Sell	-300	Closed	-$50K	–	537
2014 Q2	$50K	Buy	+300	New	+$53.4K	0.05%	380

Other funds holding CLB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

AKO Capital London, United Kingdom $4.29B AUM 4.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Seven Eight Capital's CLB Position: Q3 2020 in Review

Seven Eight Capital sold out of Core Laboratories (CLB) in Q3 2020, closing a stake of 12,226 shares — an estimated $248K sold.

Seven Eight Capital first reported a position in CLB in Q2 2014 and held it in 6 quarters. The position peaked at $1.75M in Q2 2019. 187 funds tracked by Wall St. Rank hold CLB as of Q3 2020.

Seven Eight Capital reported no remaining Core Laboratories position as of Q3 2020 after selling out during the quarter.
Seven Eight Capital sold 12,226 Core Laboratories shares in Q3 2020, an estimated $248K.
Seven Eight Capital first reported a position in Core Laboratories in Q2 2014 and held it in 6 quarters.
Seven Eight Capital's Core Laboratories position peaked at $1.75M in Q2 2019.
187 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2020.

Based on Seven Eight Capital's 13F filing for Q3 2020, filed 16 Nov 2020.